Close

Neurocrine Bio (NBIX) NBI-98854 Did Not Meet Primary Endpoin in Phase IIb Kinect

September 9, 2013 4:03 PM EDT Send to a Friend
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the 50mg dose of NBI-98854, a small molecule VMAT2 inhibitor in development ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login